English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  To assess the outcomes and prognostic factors associated with palliative external beam radiotherapy (EBRT), administered to patients with advanced gastric cancer.    Methods  Forty-two patients with bleeding gastric tumors that received EBRT for palliation were analyzed. The response to EBRT was assessed by the palliation of tumor bleeding. Patients were classified as either responders, or non-responders to EBRT. The prognostic utility of clinical and dosimetric variables was examined in a multivariate logistic regression model. The optimal dose cutoff to classify the two groups was determined with receiver operating characteristic analysis.    Results  The palliation of gastric tumor bleeding after EBRT was achieved in 29 patients (69.0%). The time to resolve tumor bleeding ranged from 1 to 84 days (median, 15 days). The median duration of palliation was 14.9 weeks. The median EBRT dose was 40 Gy in responders vs. 21 Gy in non-responders, with the difference being significant ( p  < 0.001). The biologically effective dose (using α/β = 10, BED 10 ) for responders was significantly higher than the BED 10  for non-responders (median 48 Gy vs. 26.4 Gy,  p  < 0.001), and the optimal cut off value to separate the two groups was 36 Gy ( p  < 0.001). The absence of distant metastasis and the use of concurrent chemotherapy generally showed a better EBRT response ( p  = 0.079 and  p  = 0.079, respectively). In the multivariate analysis, BED 10  ≥ 36 Gy was the most significant factor associated with EBRT response ( p  = 0.001). Overall survival (OS) and re-bleeding-free survival was median 12.6 weeks and 14.9 weeks. The responders to EBRT showed superior OS (16.6 vs. 5.1 months,  p  < 0.001). Neither acute nor chronic toxicities of grade 3 or higher were observed.    Conclusions  EBRT is an effective method for treating tumor bleeding in advanced gastric cancer, and does not induce severe toxicity.

Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer